Pharmacyclics (PCYC) Tops Q1 EPS by 32c, Revenue Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Price: $261.25 --0%
Financial Fact:
Loss from operations: 3.78M
Today's EPS Names:
FUSE, INM, TRI, More
Financial Fact:
Loss from operations: 3.78M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Pharmacyclics (NASDAQ: PCYC) reported Q1 EPS of $0.43, $0.32 better than the analyst estimate of $0.11. Revenue for the quarter came in at $206 million versus the consensus estimate of $226.27 million.
For earnings history and earnings-related data on Pharmacyclics (PCYC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- JELD-WEN Holding, Inc. (JELD) Tops Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
- Limbach Holdings (LMB) Tops Q3 EPS by 16c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
